Atara Biotherapeutics (NASDAQ:ATRA) Upgraded to Strong-Buy at TD Cowen

TD Cowen upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) to a strong-buy rating in a report issued on Friday morning,Zacks.com reports.

Several other brokerages also recently weighed in on ATRA. Canaccord Genuity Group boosted their target price on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Finally, Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their target price for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.67.

Atara Biotherapeutics Price Performance

Shares of Atara Biotherapeutics stock opened at $12.18 on Friday. Atara Biotherapeutics has a 1 year low of $6.50 and a 1 year high of $39.50. The business has a 50 day moving average price of $9.54 and a 200 day moving average price of $10.03. The company has a market capitalization of $70.13 million, a P/E ratio of -0.47 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the previous year, the business posted ($16.50) EPS. As a group, research analysts expect that Atara Biotherapeutics will post -12.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Atara Biotherapeutics by 8,916.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after acquiring an additional 4,903,159 shares during the last quarter. Vestal Point Capital LP raised its stake in Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 4,043 shares during the last quarter. FMR LLC grew its stake in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares during the period. Finally, State Street Corp increased its holdings in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.